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Summary
Paget’s disease (PD) is the most flagrant example of disor-
dered bone remodeling, with abnormalities in all phases of the
bone remodeling process. Although the basis for the abnor-
mal osteoclast (OCL) activity in PD is still unclear, several
pathophysiologic features of PD and pagetic OCL have been
demonstrated. These include: 1) pagetic OCL precursors and
OCL express the measles virus nucleocapsid protein (MVNP)
gene, suggesting a possible viral etiology for PD; 2) pagetic
OCL express increased levels of the TAFII-17 gene; 3) pagetic
OCL precursors are hyper-responsive to 1,25-(OH)2D3 a n d
RANKL, and they can form OCL at very low concentrations of
either ligand; 4) pagetic OCL has an increased rate of forma-
tion, increased nuclear number and bone resorbing capacity;
and 5) a genetic component is involved in PD. Recently, muta-
tions in the p62 gene (sequestasome-1) have been linked to
PD in a third of patients with familial PD and about 10% of pa-
tients with sporadic PD. Currently, it is unknown if both the
genetic and viral components are required for the develop-
ment of PD. However, it is clear that MVNP gene expression in
pagetic OCL precursors results in development of the pagetic
phenotype in OCL. The genetic component appears to in-
crease basal osteoclastogenesis but by itself may not be suffi-
cient to induce PD.
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Introduction
Paget’s disease (PD) of bone was first described in 1876 by
James Paget as a disease that begins at middle-age or later
and affects the long bones of the lower extremities, the pelvis
and the skull. The bones enlarge and soften, and those bearing
weight yield and become unnaturally curved or misshapen (1).
This description remains accurate, although not all patients ex-
perience bone deformities. A recent study estimates that up to
70% of patients may be asymptomatic (2). Bone pain is the
most common complication. Other symptoms may include
deafness, nerve compression syndrome and pathological frac-
tures (3). The most devastating complication of PD is osteo-
clastoma, which is a very rare complication of the disease and
occurs in less than 1% of patients. However, the vast majority
of osteosarcomas in adults occur in patients with PD.
PD is particularly prevalent in populations of Northern Euro-
pean ancestry. Recently, the prevalence of the disease in the
United States has been estimated to be approximately 1.3% in
the population over the age of 55, which is a decrease from
5.4%, estimated in the 1970s (2). A similar decline in disease
prevalence has also been reported in New Zealand (4). A cur-
rent prevalence of 2% has been estimated in the United King-
dom (5). The prevalence of PD increases with age, such that
the prevalence in the population over the age of 85 is almost 5
times that of the population under the age of 60. Differences in
disease incidence is found at different geographic locations
with a particular hot spot in the Lancashire region in the United
Kingdom. PD is the second most common bone disease in the
population over the age of 55 in the United States, the United
Kingdom, and in other Caucasian populations. 
PD is primarily a disease of osteoclasts (OCL) with abnormal
function. This in turn leads to excessive osteoblast activity and
is reflected in serum alkaline phosphatase, which is elevated in
85% of patients. Bisphosphonates, by inactivating OCL, in turn
normalize the osteoblast activity, indicated by a reduction in
serum alkaline phosphatase. X-rays and isotope bone scans
are used to identify affected skeletal sites. PD can affect one or
multiple bones, and is highly localized. The disease can spread
within a particular site, but it rarely spreads to new sites. This
feature distinguishes PD from three more progressive diseases
with similar bone histology: Familial Expansile Osteolysis
(FEO), Expansile Skeletal Hyperphosphatasia (ESH), and Ju-
venile Paget’s Disease (JPD).
Bone histology and OCL phenotype in PD
Typical features of bones involved with PD include excessive
numbers of OCL, which in turn are increased in size and nu-
clear number per OCL (Figure 1), large numbers of highly ac-
tive osteoblasts, the presence of woven bone and often a high-
ly cellular bone marrow.
Pagetic OCL have been extensively investigated by TEM and
immunohistochemistry (Figure 2) ever since they were first re-
ported to contain intranuclear, or less frequently, intracytoplas-
mic inclusions. Intranuclear inclusions are found in almost all
cases of PD (6) and the perceived similarity of these structures
to paramyxovirus nucleocapsids (7) has led to the hypothesis
that PD may be caused by a persistent infection by measles
virus (MV) or another paramyxovirus (8, 9). This issue remains
unresolved as evidence for or against the role of paramyx-
oviruses in the etiology of this disease has been presented
over many years (10,11). The inability of various groups work-
ing in this field to confirm each other’s findings has continued
the discussion.
Reddy et al. reported the presence of measles virus nucleo-
capsid sequences in patients with PD, which can be amplified
from bone marrow, blood cells, and early hematopoietic
colony-forming cells in the United States (12). Recently, the
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amplification of a complete measles coding sequence has
been reported (13). Contrary to these results, Mee et al. had
reported the presence of canine distemper virus, but not
measles virus (14). However, others were unable to detect any
paramyxovirus in Paget’s patients (15). No intact virus has ever
been recovered from a patient with PD. Not only has the pres-
ence of viral nucleic acids in pagetic tissue been questioned,
but the whole basis for considering paramyxovirus in the etiolo-
gy of the disease (15), since the intranuclear inclusions in PD
are ultrastructurally dissimilar to these seen in subacute scle-
rosing panencephalitis (SSPE), the only known persistent
measles infection (11). 
In support of the role for a virus in the etiology of PD, however,
are our studies indicating that measles virus infection of murine
OCL, made susceptible by transfection with the human
measles virus receptor (CD46), resulted in pagetic features in
OCL, specifically enhanced nuclearity (16). The final analysis
of a viral involvement in PD must await the elucidation of the
undisputed genetic component in this disease (17). Only once
the predisposing/causative genes have been identified will it be
possible to assess whether viral infection is required for ex-
pression of the full phenotypic features of the disease.
In vitro study of pagetic OCL
Bone marrow culture techniques that allow the formation of
O C L s in vitro have provided new insights into the potential
pathogenesis of PD. Our laboratory was the first to examine
OCL formation from bone marrow obtained from involved
bones from patients with PD (18, 20). In vitro, increased num-
bers of OCLs are formed by pagetic precursors, and OCL are
larger and contain more nuclei than in controls. 
We found that multinucleated cells that formed in marrow cul-
tures from Paget’s patients shared many of the characteristics
of pagetic OCLs. The OCLs were increased in number (10- to
100-fold) compared to normal marrow cultures, had increased
numbers of nuclei per multinucleated cell (up to 100 nuclei per
cell as compared to 3-10 nuclei in normal OCL), and expressed
high levels of tartrate-resistant acid phosphatase (TRAP). This
appears to be caused by the fact that the precursors are hyper-
responsive to 1,25-(OH)2D3 and RANKL (18-21), rather than
through an increase in the number of OCL precursors. 
Immunocytochemical studies confirmed that MV and respirato-
ry syncytial virus nucleocapsid antigens were expressed in
OCLs formed in vitro in these cultures (22). OCL formation
was induced by concentrations of 1,25(OH)2D3 that were 1 to
2 logs lower than that required for OCL formation in normal
marrow cultures, suggesting that OCL precursors from Paget’s
patients were hyper-responsive to 1,25(OH)2D3 (20). In sup-
port of this finding, Kurihara et al. have shown that transduc-
tion of normal OCL precursors, CFU-GM, with retroviral con-
structs containing the cDNA for the M V N P gene, induce OCL
precursors to form OCL that express a pagetic phenotype and
are hyper-responsive to 1,25-(OH)2D3 (23). They have further
shown that using GST-VDR chimeric protein pull-down assays
with lysates from MV N P transduced normal OCL precursors
and marrow cells from involved bones from patients with PD,
that a potential coactivator of VDR, TAFI I-17 (24), which is not
expressed in normal OCL precursors, is overexpressed in
pagetic OCL and may be playing a role in the hyper-respon-
sivity to 1,25-(OH)2D3 (25). The molecular basis for the in-
creased affinity of 1,25-(OH)2D3 for the VDR appears to result
from enhanced expression of co-activators that interact with
VDR, in particular TAFI I-17, a member of the TFI ID transcrip-
tion complex (24, 25). Menna et al. had also shown that OCL
precursors from patients with PD are also hyper-responsive to
RANK ligand (26). 
VDR coactivator expression in PD
As noted above, one of the earliest findings from in vitro stud-
ies of PD is that pagetic OCL precursors are hyper-responsive
to 1,25-(OH)2D3 and form OCL at concentrations of 1,25-
( O H )2D3 that are physiologic rather than pharmacologic. The
increased responsivity to 1,25-(OH)2D3 is not due to increased
levels of the Vitamin D receptor (VDR) nor to increased affinity
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Figure 1 - Osteoclasts in Paget’s disease. Pagetic osteoclasts are in-
creased in both number and size and contain increased nuclei per mult-
inucleated cells. In addition, these cells show an increased bone re-
sorbing capacity. 
Figure 2 - Transmission Electron Microscopy (TEM) and immunocyto-
chemistry of osteoclasts from patients with Paget’s disease. A viral ti-
ology has been suggested for Paget’s disease. Paramyxoviral-like nu-
clear and cytoplasmic inclusions are present in osteoclasts from the
majority of patients (A). Immunocytohistochemical studies have shown
that pagetic osteoclasts express measles virus and respiratory syncytial
virus nucleocapsid antigens (B). 
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of 1,25-(OH)2D3 for VDR. Kurihara et al. had shown by using
GST-VDR chimeric protein pull-down assays that TAFI I-17, a
member of the TFI ID transcription complex, is increased in
OCL precursors from patients with PD compared to normals.
Kurihara et al. further showed that TAFI I-17 could enhance
VDR mediated gene transcription and allow formation of the
transcription complex at very low levels of 1,25-(OH)2D3. In ad-
dition, other coactivators of VDR, including CPB/p300 and
DRIP205, are also increased in OCL precursors from Paget’s
patients (27). These data suggest that the enhanced sensitivity
of OCL precursors to 1,25-(OH)2D3 in PD results from in-
creased expression of coactivators of VDR.
Expression of the pagetic phenotype in OCL requires VDR
dependent gene transcription
Transduction of normal CFU-GM with retroviral constructs con-
taining the cDNA for the measles virus nucleocapsid (MVNP)
gene can induce these cells to form OCL that express a
pagetic phenotype and are hyper-responsive to 1,25-(OH)2D3.
This result suggested that VDR plays a key role in the abnor-
mal OCL activity in PD. Therefore, to test this hypothesis, OCL
precursors from VDR-/- and VDR+/+ mice were transfected
with the M V N P gene, and the characteristics of OCL formed
examined. PCR analysis of MVNP transduced VDR-/- and
VDR+/+ OCL precursors demonstrated that both cell types ex-
pressed high levels of TAFII-17. OCL formation was significant-
ly decreased in bone marrow cultures from VDR -/- mice treat-
ed with RANKL compared to marrow cultures from VDR +/+
mice. Furthermore, the OCL that formed in marrow cultures of
VDR -/- mouse transfected with the M V N P gene did not ex-
press a pagetic phenotype. In contrast, MVNP transfected
VDR+/+ mouse cells treated with RANKL formed large num-
bers of abnormal OCL that expressed a pagetic phenotype. As
expected, VDR-/- marrow cells did not form OCL in response to
1 , 2 5 - ( O H )2D3. These data suggest that VDR mediated gene
transcription may be required for expression of a pagetic phe-
notype in OCL.
Genetics of PD 
PD is a complex disease where multiple genetic factors have
been identified. A genetic component appears to be involved in
PD, with at least six loci now linked to PD. 
The genetic basis for PD stems from the observation that famil-
ial clustering is common and that ethnic differences in preva-
lence persist after migration. Between 15-40% of patients have
an affected first-degree relative, and first-degree relatives have
a seven-fold increased risk of developing the disease com-
pared to controls (28). Familial PD has an autosomal dominant
mode of inheritance with high penetrance. Linkage analysis in
families initially concentrated on HLA alleles and a susceptibili-
ty locus was described on chromosome 6q21 (29). 
However, further studies, including genome wide searches,
have failed to confirm this region as important in PD (30,31).
Following the cloning of RANK and the realization that RANK is
critical for OCL differentiation (32) led to the examination of
chromosome 18 in PD, RANK maps to critical region on chro-
mosome 18q, previously linked to FEO, a more serve disease
with clinical and histological similarities to PD. Linkage studies
also explored the involvement of 18q21-22 and mutations in
RANK in PD. Linkage to 18q21-22 was found in a number of
families (33,34), however, only one Japanese family with se-
vere, early onset PD was found to have a mutation in RANK
(35). It is now well-established that PD is rarely linked to
18q21-22 (36) and mutations in RANK and OPG genes do not
give rise to adult PD (37), but rather, to more severe, early on-
set disorders.
Having found a link of PD to chromosome 5q in a number of
French-Canadian families, Laurin et al. (38) recently described
a non-conservative heterozygous point mutation in a novel
gene, sequestosome 1 (SQSTM1) in 11% of familial and 16%
of sporadic PD (38). Mutations in p62 are the most frequently
reported genetic mutations and affects about 26% of patients
with familial PD and 9% of sporadic cases (39). More recently,
the identification of new mutations in SQSTM1 have been re-
ported in the Netherlands (40) and Belgian patients with PD
(41). 
In the familial PD, the mutations co-segregated with the dis-
ease but were seen in small numbers of unaffected family
members but not in a large number of non-pagetic controls.
These data indicated that these mutations may not by them-
selves be sufficient to cause PD. S Q S T M 1 codes for p62, a
widely expressed ubiquitin-binding protein (41), which acts as a
scaffold protein in the NF-kB signaling pathway, facilitating
TNF-a, CD40 and IL-1 through its interactions with the atypical
protein kinases, zPKC or l PKC (42-44). 
The mutations found in PD so far are all predicted to affect the
ubiquitin-binding domain of the protein and to abolish or re-
duce ubiquitin binding. The P392L mutation is the most fre-
quent mutation reported. The biological consequences of p62
remain to be substantiated in transgenic mice and knockout
mice (45) and further in vitro experiments. Whereas ubiquiti-
nated proteins, destined for degradation in the proteasome,
generally bind ubiquitin in a covalent manner on single
residues, p62 appears to use a large domain to bind ubiquitin
in a non-covalent manner. Given this difference, it is unclear
whether ubiquitin binding by p62 leads to its own degradation,
or whether instead it has a role to play in regulating ubiquitina-
tion of other signaling molecules by controlling intracellular
availability of ubiquitin. Further cell biological experiments are
required to elucidate the role of p62 and its specific impor-
tance in OCL formation. Recently, we have targeted p62
(P392L) to the OCL lineage in transgenic mice. These mice
show increased OCL formation and activity but do not develop
PD by age 4 months.
The genetics of PD is under intense investigation and the oth-
er genes mutated in PD will, no doubt, soon be found in the
remaining susceptibility loci. Only once all the genes involved
in this heterogeneous disorder have been identified will it be
possible to examine fully the etiology and biology of the dis-
ease. Transgenic mice, harboring the various mutations
found in patients, may be useful as models, but may not de-
elop the disease unless exposed to appropriate environmen-
tal triggers, for example, viral infection, ageing or fracture.
Such studies will be complex, but may provide the only tool to
help dissect their contribution to disease development. In ad-
di ion, such studies will help to provide a better understanding
of the unique role of the primary genes affected in the biology
of the OCL.
Conclusion
PD appears to require both a genetic and environmental factor.
VDR mediated gene transcription is required for expression of
a pagetic phenotype in OCL, and the p62MUT causes increased
NF-kB signaling and OCL formation in response to RANKL and
T N F -a. MVNP increases 1,25-(OH)2D3 responsivity and in-
duces TAFI I-17. These data suggest that p62M U T i n c r e a s e s
basal OCL formation in PD patients but is not sufficient to in-
duce the complete PD phenotype in OCL precursors without an
environmental component that affects VDR mediated gene
transcription.
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